key: cord-1014367-d336tcts
authors: Meyerowitz, Eric A; Sen, Pritha; Schoenfeld, Sara R; Neilan, Tomas G; Frigault, Matthew J; Stone, John H; Kim, Arthur Y; Mansour, Michael K
title: Immunomodulation as Treatment for Severe COVID-19: a systematic review of current modalities and future directions
date: 2020-11-20
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1759
sha: 5d15458b35fe075b90fb67a20e13f5b9e1625d6d
doc_id: 1014367
cord_uid: d336tcts

In SARS-CoV-2 infection, the viral load peaks early setting off a cascade of immune dysregulation that persists well after viral clearance. Severe COVID-19 is marked by aberrant innate and adaptive immune responses with an abnormal cytokine profile and a prolonged illness course with multisystem organ dysfunction. Antiviral treatments have yet to show benefit later in critical illness. Taken together, this raises the concern that a purely antiviral treatment approach may be insufficient. A number of immunomodulatory strategies are being tested, including corticosteroids, cytokine and anti-cytokine therapies, small molecule inhibitors, and cellular therapeutics. The only drug to date to show a mortality benefit for COVID-19 in a randomized control trial is dexamethasone, but there remains uncertainty about which patients may benefit most and longer-term complications including secondary infections. Here we review the immune dysregulation of severe COVID-19, the existing data behind various immunomodulatory strategies, and consider future directions of study.

Infection with severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) results in a wide spectrum of disease. Among individuals with symptomatic coronavirus disease 2019 (COVID-19), approximately 15-20% are estimated to develop severe presentations requiring supplemental oxygen, including up to 5% who may develop critical illness. [2] Infection fatality rates are population and age dependent, with very low rates for children and young adults but mortality rates >25% for individuals over age 90. [3] Areas with rapid surges of infections, associated with delayed access to care, may have higher fatality rates, as was found in Spain and New York City. [4, 5] The explanation for the profound differences in disease severity stratified by age are unknown and likely multifactorial. Current theories include possible increased likelihood of cross-protective cellular immune response from recent infection with common human coronaviruses and age-related changes in immunity, including decreased availability of naïve T cells to respond to new viral antigens in older adults. [6] [7] [8] Autopsy studies demonstrate that the primary pulmonary pathology is diffuse alveolar damage, with micro and macrovascular thrombosis. [9] Symptomatic patients typically develop mild symptoms during an acute viral phase although a subset of patients will progress to severe disease that can last weeks and often requires hospitalization. [10] [11] [12] This severe stage is typically marked by immune dysregulation and abnormal inflammatory markers ( Figure 1 ). Higher upper respiratory tract viral loads are associated with more severe presentations. [13, 14] Numerous therapeutic agents are currently under investigation for treatment of COVID-19. During the early phase of the pandemic, many agents were given off label or in the context of randomized controlled trials (RCTs). While we will review randomized and non-randomized series here, it is important to note that only data from high quality RCTs should change practice in the next phase of the pandemic.

The main therapeutic strategies are direct antiviral and immunomodulatory approaches. To date, remdesivir, a nucleoside analogue that targets the viral RNA dependent RNA polymerase, has the most A c c e p t e d M a n u s c r i p t 4 supportive data. It has shown efficacy when given early to rhesus macaques as well as improvement in time to recovery in a large RCT compared to placebo called the Adaptive COVID-19 Treatment Trial (ACTT)-1. [15] [16] [17] There was a suggestion of a mortality benefit in patients on supplemental oxygen but not in the ICU, with no or minimal survival benefit seen for those with critical disease. [17] [18] [19] A challenge to antiviral therapy for COVID-19 is that patients with severe disease tend to present after 5-7 days of symptom when viral loads are declining. [20, 21] The only agent yet to show a mortality benefit for COVID-19 is dexamethasone. In a large open label, UK-based RCT called RECOVERY, over 6000 patients were randomized in a 1:2 fashion to dexamethasone or standard of care, with a lower mortality recorded in the dexamethasone group (22.9% vs 25.7%, p<0.001). The benefit was largest in those who were mechanically ventilated and there was no benefit among those without hypoxemia. Additionally, a mortality benefit was seen for those who received dexamethasone after 7 days of symptoms, but not if they received the agent before that time. [22] That remdesivir has not shown a significant benefit in critically ill patients and that the mortality benefit with dexamethasone is strongest in this group (and after 7 days of symptoms) further suggests a viral followed by an immune dysregulation phase.

That immunomodulation might impact COVID-19 outcomes is also suggested from some epidemiologic studies. While confounding and indication bias need to be considered, rheumatologists and inflammatory bowel specialists report early data suggestive of a lower incidence of severe COVID-19 for patients prescribed TNF- inhibitors compared with similar cohorts on chronic steroids. [23, 24] [ Figure 1 ] A c c e p t e d M a n u s c r i p t 5

We searched for English-language titles, abstracts and relevant articles from LitCovid, an electronic literature hub for COVID-19-related articles indexed on PubMed from January 2020 through October 21, 2020 using terms including corticosteroids, methylprednisolone, dexamethasone, tocilizumab, sarilumab, ruxolitinib, baricitinib, anakinra or interferons. All RCTs were included, regardless of study size. Non-randomized studies of at least 50 individuals treated with corticosteroids or tocilizumab were included. For other agents, reports were included if ≥20 individuals received the treatment. When no peer reviewed data were available, press releases and preprints for major were included.

Early descriptions of patients with severe COVID-19 reported marked derangements in inflammatory markers, including elevated levels of interleukin-6 (IL-6), ferritin, and C-reactive protein A c c e p t e d M a n u s c r i p t 6 acute respiratory distress syndrome.[34, 35] Therefore it has become clear that severe or critical COVID-19 is not a true cytokine storm state.

The picture that is emerging is far more complex, with dysfunction of both the innate and adaptive immune system contributing to severe COVID-19. Transcriptional changes in host cells after SARS-CoV-2 infection include upregulation of cytokines such as IL-6 and IL-1 receptor antagonist as well as reduced interferon expression. There is also induction of other cytokines and chemokines, including CCL2 and CCL8 (which recruit macrophages) and CXCL2 and CXCL8 (which recruit neutrophils The adaptive immune response to SARS-CoV-2 infection is also under intense study. A coordinated early adaptive immune response with generation of SARS-CoV-2 specific CD4+ and CD8+ T cells and neutralizing antibodies is associated with less severe outcomes.

[8] CXCL10 has been found to A c c e p t e d M a n u s c r i p t 7 have a strong negative correlation with SARS-CoV-2 specific T cell responses and has been proposed as a potential biomarker for poor T-cell responses in severe COVID-19.

[8]

A now well described inflammatory syndrome related to COVID-19, multisystem inflammatory syndrome in children (MIS-C), may have clinical features of Kawasaki disease with some patients also meeting criteria for macrophage activation syndrome. [44] [45] [46] [47] The syndrome is now also well described in adults.

[48] These cases are often diagnosed weeks after SARS-CoV-2 infection and treatment includes IVIG and other immunomodulating agents like steroids or anakinra. There is some overlap between the immune changes associated with this syndrome and those seen in severe COVID-19, including lymphopenia, elevation of various cytokines, and impaired antigen presentation.

[49]

Corticosteroids are widely used immunomodulatory agents for a variety of conditions. There was initial hesitation in using them for COVID-19 given an association with prolonged viral shedding when used for other SARS or MERS in non-randomized settings.

[50] Steroid use in non-COVID-19-related ARDS has mixed results, with some studies suggesting a possible mortality benefit; however, steroid use for influenza pneumonia is associated with increased mortality.[51, 52] We identified 531 references on "steroids," "dexamethasone," or "methylprednisolone" and included 14 studies ( The mortality benefit was more modest for individuals receiving supplemental oxygen but not requiring mechanical ventilation, 23.3% vs. 26.2%, rate ratio 0.82, 95%CI 0.72-0.94. Importantly among those not receiving supplemental oxygen there was no benefit seen and, indeed, a trend towards harm, 17.8% vs.

14.0%, rate ratio 1.19, 95%CI 0.91-1.55. The mean time from symptom onset for those not on supplemental oxygen was 6 days compared with 8 days for those with supplemental oxygen and 13 days for those requiring mechanical ventilation. In fact, when considering the subgroup started on steroids before 7 days of symptoms, there was no mortality benefit seen. The heterogeneity seen in the results of this trial suggests that a one-size-fits-all approach is not appropriate for treatment of COVID-19. Based on data from RECOVERY, there is strong evidence for steroid administration, preferably dexamethasone, for individuals with COVID-19 requiring supplemental oxygen or mechanical ventilation, particularly if they are beyond 7-days of symptom onset. Steroids should be avoided for individuals not requiring supplemental oxygen.

[ Table 1 ]

Besides steroids, numerous other immunomodulatory agents have been used for COVID-19. An early report from China used IL-6 receptor blocker (tocilizumab) for the treatment of 21 patients with severe or critical disease and reported rapid and profound improvement in oxygenation, inflammatory markers, and clinical status, generating tremendous interest.

[69] Our systematic evaluation identified 412 tocilizumab and 14 sarilumab peer reviewed articles related to COVID-19, of which, 13 were included here ( Table 2) . A preprint and two press releases of major RCTs were also included. The results from the non-randomized studies are mixed. Importantly peer reviewed results from one double blind RCT and two open-label RCTs are now available, and additional RCT results are available by preprint and press release. The results from the RCTs are largely concordant, with neither benefit nor an increased risk of secondary infections. One trial reports a benefit because a composite primary endpoint was met, but mortality at 28-days was numerically higher in the tocilizumab arm.

[70] These accumulating negative A c c e p t e d M a n u s c r i p t 9 suggest that COVID-19 is not a true cytokine, specifically IL-6 mediated, storm but rather the result of more complex immune dysregulation. Additional peer-reviewed data are forthcoming, but at this time there is no evidence to support the use of IL-6 receptor inhibition for treatment of COVID-19.

[ Table 2 ]

Use of other immunomodulatory agents is described in fewer publications. These agents include anakinra (3 studies), baricitinib (2 studies), and ruxolitinib (1 study) ( Table 3 ). Treatment of COVID-19 with interleukin-1 receptor antagonism with anakinra has been studied, with no RCTs published to date.

Two small non-randomized series have suggested a mortality benefit with this agent, but there are currently no data to support using this agent outside of a clinical trial. A c c e p t e d M a n u s c r i p t 10 Interferon therapy is another immunomodulatory approach being studied for treatment of COVID-19. SARS-CoV-2 is sensitive to type I interferons in vitro with markedly decreased viral replication.

[95] SARS-CoV-2 evades the interferon response and insufficient interferon stimulation is seen in patients with severe COVID-19.

[96] Taken together, this observation has led to the hypothesis that early type I interferon administration might help limit viral replication. The MIRACLE trial for MERS, which is the first RCT published for treatment of either SARS or MERS, found that interferon beta1b was associated with lower mortality in a prespecified subgroup when it was given within 7 days of symptom onset but had no effect later in the illness course. (Table 4 ). An open label RCT evaluated treatment with triple therapy (interferon -1b, ribavirin, and lopinavir/ritonavir) against lopinavir/ritonavir monotherapy and found that the interferon treated group had faster viral clearance from nasopharyngeal swabs of 7 days versus 12 days (p=0.001).

[101] This striking result is notable since no other randomized treatment study has demonstrated such impact, including a remdesivir study, [15] and suggests that specific immune augmentation may have potent anti-SARS-CoV-2 viral effect. Preliminary data from the large WHO-sponsored SOLIDARITY trial suggest interferon beta1b administration was not associated with a change in mortality, but there is no information about the timing of administration.

[19] Currently there are insufficient data to support interferon use for COVID-19 outside of a clinical trial, but further study, particularly early in disease, is needed. Given the finding of auto-antibodies to some type I interferons (most commonly interferon alpha) in severe COVID-19, interferon-beta formulations may be more likely to have effect than interferon-alpha. [40] A c c e p t e d M a n u s c r i p t 11 [ Table 4 ]

Therapy Some immunomodulatory agents are associated with an increased risk of secondary infections.

Notably, tocilizumab in the setting of CAR-T-related CRS is not associated with increased infection risk Given the marked heterogeneity of COVID-19 clinical presentations, therapeutic approaches will likely need to be tailored to individual patients and a one-size-fits all approach may not provide optimal benefit. Potential therapeutic approaches will need to identify the right therapy, dose, patient and proper timing in relation to the disease course. To define these specific treatments, data from well performed A c c e p t e d M a n u s c r i p t Table 1 Legend: a n = number of patients in study who received immunomodulatory therapy b Strength of evidence graded as: A = from a randomized control trial, B = from a non-randomized study RCT = randomized controlled trial. 95% CI = 95% confidence interval range, HR = hazard ratio, SpO2 = peripheral capillary oxygen saturation, CRP = Creactive protein, IL-6 = interleukin 6, ARDS = acute respiratory distress syndrome, ICU = intensive care unit, OR = odds ratio, aOR = adjusted odds ratio, fiO2 = fraction of inspired oxygen M a n u s c r i p t 34 Table 2 Legend: a n = number of patients in study who received immunomodulatory therapy b Strength of evidence graded as: A = from a randomized control trial, B = from a non-randomized study RCT = randomized controlled trial. 95% CI = 95% confidence interval range, HR = hazard ratio, aHR = adjusted hazard ratio, SpO2 = peripheral capillary oxygen saturation, CRP = C-reactive protein, IL-6 = interleukin 6, ARDS = acute respiratory distress syndrome, ICU = intensive care unit, OR = odds ratio, aOR = adjusted odds ratio, fiO2 = fraction of inspired oxygen, PaO2 = partial pressure of oxygen, RR = respiratory rate, TCZ = tocilizumab, HCQ = hydroxychloroquine, LPV/r = lopinavir with ritonavir, RDV = remdesivir, IFN- = interferon beta, DRV/c = darunavir with cobicistat

Division of Infectious Diseases

Massachusetts General Hospital, Boston MA 5. Division of Hematology and Oncology

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

SYSTEMATIC REVIEW

COVID-19 Infection Fatality Rate Associated with Incidence-A Population-Level Analysis of 19 Spanish Autonomous Communities

Estimating the infection fatality risk of COVID-19

during the spring 2020 pandemic wave. medRxiv 2020: 2020.06.27

A c c e p t e d M a n u s c r i p t M a n u s c r i p t 39 Table 3 Legend: a n = number of patients in study who received immunomodulatory therapy b Strength of evidence graded as: A = from a randomized control trial, B = from a non-randomized study RCT = randomized controlled trial. 95% CI = 95% confidence interval range, HR = hazard ratio, aHR = adjusted hazard ratio, SpO2 = peripheral capillary oxygen saturation, CRP = C-reactive protein, ICU = intensive care unit, OR = odds ratio, aOR = adjusted odds ratio, fiO2 = fraction of inspired oxygen, PaO2 = partial pressure of oxygen, RR = respiratory rate, TCZ = tocilizumab, PCR = polymerase chain reaction A c c e p t e d M a n u s c r i p t 41 Table 4 Legend: a n = number of patients in study who received immunomodulatory therapy b Strength of evidence graded as: A = from a randomized control trial, B = from a non-randomized study RCT = randomized controlled trial. 95% CI = 95% confidence interval range, HR = hazard ratio, aHR = adjusted hazard ratio, SpO2 = peripheral capillary oxygen saturation, CRP = C-reactive protein, IL-6 = interleukin 6, ARDS = acute respiratory distress syndrome, ICU = intensive care unit, OR = odds ratio, aOR = adjusted odds ratio, fiO2 = fraction of inspired oxygen, PaO2 = partial pressure of oxygen, RR = respiratory rate, TCZ = tocilizumab, HCQ = hydroxychloroquine, CQ = chloroquine, LPV/r = lopinavir with ritonavir, RDV = remdesivir, IFN- = interferon beta, DRV/c = darunavir with cobicistat, ATV/r = atazanavir with ritonavir, NEWS2 = National Early Warning Score 2, PCR = polymerase chain reaction, IVIG = intravenous immunoglobulin A c c e p t e d M a n u s c r i p t